HC Wainwright & Co. Maintains Buy on Innate Pharma, Raises Price Target to $7
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $5 to $7.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $5 to $7.